Edition:
United States

Puma Biotechnology Inc (PBYI.N)

PBYI.N on New York Stock Exchange

40.87USD
1:30pm EDT
Change (% chg)

$-0.65 (-1.57%)
Prev Close
$41.52
Open
$41.29
Day's High
$41.40
Day's Low
$40.18
Volume
57,759
Avg. Vol
144,479
52-wk High
$106.99
52-wk Low
$19.74

PBYI.N

Chart for PBYI.N

About

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is... (more)

Overall

Beta: 0.05
Market Cap(Mil.): $1,349.11
Shares Outstanding(Mil.): 32.49
Dividend: --
Yield (%): --

Financials

  PBYI.N Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -7.97 -- --
ROI: -109.22 -5.86 14.35
ROE: -109.87 -4.70 15.56

U.S. RESEARCH ROUNDUP-D.R. Horton, Humana, Chicago Bridge & Iron

July 22 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adeptus Health, Chipotle Mexican Grill and Yadkin Financial, on Friday. HIGHLIGHTS * Chicago Bridge & Iron Co : Baird cuts to neutral * D.R. Horton Inc : BofA Merrill cuts to neutral from buy * Humana Inc : Wolfe Research raises to outperform * Community Bank System Inc : Sandler O'Neill cuts to

Jul 22 2016

BRIEF-Puma Biotech applies for marketing approval for breast cancer drug

* Submits NDA for PB272 (neratinib) to U.S. FDA for extended adjuvant treatment of HER2-positive early stage breast cancer Source text for Eikon: Further company coverage:

Jul 21 2016

BRIEF-Puma Biotechnology announces 5-year data on breast cancer

* "look forward to obtaining full 5-year dfs data, which we anticipate will be available in 2017"

Jul 21 2016

BRIEF-Puma Biotechnology Inc submits MAA for neratinib

* Puma biotechnology submits marketing authorization application (MAA) for PB272 (neratinib) as extended adjuvant treatment of her2-positive early stage breast cancer in europe

Jun 27 2016

BRIEF-Paulson & Co ups share stake in Puma Biotechnology Inc by 52.8 pct to 70,300 shares - Sec Filing

* Paulson & Co ups share stake in Puma Biotechnology Inc by 52.8 pct to 70,300 shares - Sec Filing

May 16 2016

BRIEF-Puma Biotechnology reports Q1 loss per share $2.19

* Puma biotechnology reports first quarter 2016 financial results

May 10 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00
Provider : Pechala's Reports
$25.00
Provider : GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.